Digital Landscape: Inflammatory Bowel Disease

2018-09-06
Price :
Published : Sep-2018
No. of Pages : 159

Digital Landscape: Inflammatory Bowel Disease

Summary

The Digital Landscape Inflammatory Bowel Disease report analyzes digital activities undertaken by pharma in support of disease-modifying therapies for mild-to-moderate, and moderate-to-severe Crohn’s disease and ulcerative colitis (UC).

Key Highlights

– US Patients: AbbVie offers the strongest support for IBD patients in the US, particularly branded, unbranded and mobile app. Janssen was the most active competitor in the branded and social media spaces in 2017. Branded activity also seen from pipeline and biosimilar competitors. No IBD-specific mobile apps detected from pharma. Opportunity exists for a well-integrated unbranded campaign to support patients, linked to social media and a mobile app.
– US HCPs: Good support available for US HCPs in the IBD branded space, with Stelara and Humira activity detected from Janssen and AbbVie in 2017, respectively. Unbranded and mobile app landscapes are sparse. Opportunities may exist to develop or sponsor content with trusted non-pharma organizations; social media activity restricted to corporate accounts.
– EUCAN Patients: Good brand support for patients in Germany, the UK, and Canada, with IBD-specific activity detected from Takeda and Janssen in 2017. No multi-country unbranded from biologics manufacturers with Ferring providing the only example. Unbranded support is strongest in Germany overall, with new sites launched by Janssen and Pfizer in 2017. Social media support is weak overall; EUCAN IBD patients have access to good mobile app offerings, however none detected in Italy.
– EUCAN HCPs: The EUCAN HCP landscape is underdeveloped. Most branded activity limited to Germany or the UK with all new activity seen in the UK in 2017. The unbranded and mobile app landscapes are particularly sparse, and partnerships with non-pharma organizations may offer more effective opportunities to engage with and support HCPs.

Scope

– This report analyzes digital activities undertaken by pharma in support of therapies for disease-modifying therapies for mild-to-moderate, and moderate-to-severe Crohn’s disease and ulcerative colitis (UC).
– The report includes digital activities directed towards patients and/or HCPs, including branded websites, unbranded disease awareness initiatives, social media and mobile apps.
– The report is based on analysis conducted by a combination of GlobalData’s digital and disease-specific teams. It also includes analysis of data licensed from third parties e.g. website traffic, search engine optimization (SEO), digital display advertising, mobile app downloads, and social media interaction.
– The geographic scope of the report is the United States, Canada and the 5EU (UK, Germany, France, Italy & Spain), with EUCAN used as an abbreviation for Europe and Canada throughout.
– This report covers the research period from January – December 2017.

Reasons to buy

– Our Digital Landscape report provides an analysis of pharma multichannel activity in the digital IBD space, and can assist our pharma clients derive value in a number of ways –
– Competitive Intelligence: Track and compare key competitor activity across channels and identify key trends in IBD
– Digital Strategy: Strengthen corporate digital excellence, learn from industry best practice, and identify opportunities for novel digital campaigns
– Support new brand launch: See best practice examples of pre- and post-launch digital activities, ascertain must-have digital assets for patient and HCP engagement, and assess potential gaps and opportunities for pipeline brands
– Business Development & Licensing: Assess topics and trends shaping digital health in IBD and beyond, and learn about key patient and physician online activities in IBD.

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
Publisher : GlobalData
More Reports
Title Price Buy Now

Digital Landscape: Breast Cancer

Digital Landscape: Breast Cancer Summary The "Digital Landscape: Breast Cancer", report analyzes digital activities undertaken by pharma in support of therapies for breast cancer. Key Highlights - US Patients: Strong digital support for US breast cancer patients in the US, particularly from Pfizer, Novartis and AstraZeneca. Most recent branded activity seen from Lilly and Novartis in the CDK4/6 inhibitor space. Most unbranded and social media activity focuses on supporting patients with metastatic breast cancer. Few breast cancer-specific mobile apps detected in the US. - US HCPs: There is little support for HCPs in the breast cancer space beyond branded. AstraZeneca, Genentech, Novartis and Pfizer offer examples of strong branded resources. The pharma-sponsored unbranded and ......
$6000

PharmSource – Contract Dose Manufacturing Industry by the Numbers: Composition, Size, Market Share and Outlook – 2018 Edition

PharmSource - Contract Dose Manufacturing Industry by the Numbers: Composition, Size, Market Share and Outlook - 2018 Edition Summary The motivation for pharma companies outsourcing their manufacturing is often to do with lacking expertise, equipment, or cost reduction (especially for small to mid-sized CMOs) in development of their product's API or dose. For clinical dose manufacturing, there is a high risk associated with the pipeline drug product and as such using a CMO for this mitigates risk for pharma companies that may otherwise have to invest in equipment and facilities. This report, the 2018 version in this annual series, characterizes the contract dose manufacturing industry along a number of quantitative dimensions, including number and type of participants, market size, m......
$4995

Healthcare Industry Business Outlook and Procurement Report July 2018 – December 2018

Healthcare Industry Business Outlook and Procurement Report July 2018 - December 2018 Summary GlobalData's "Healthcare Industry Business Outlook and Procurement Report July 2018 - December 2018", examines executives' opinions on the business outlook and procurement activities over July-December 2018. Organizations can know about key business priorities, changes in capital expenditure, global revenue contributors, and key information about the organizations' digital transformation strategies along with investment in emerging technologies. Additionally, it provides information categorized by region and company types. The highest percentages of healthcare industry executives identify expansion in the current market and new product development as the foremost priorities of healthcare ......
$1950

House Dust Mite Allergy Global Clinical Trials Review, H2, 2018

House Dust Mite Allergy Global Clinical Trials Review, H2, 2018 Summary GlobalData's clinical trial report, "House Dust Mite Allergy Global Clinical Trials Review, H2, 2018" provides an overview of House Dust Mite Allergy clinical trials scenario. This report provides top line data relating to the clinical trials on House Dust Mite Allergy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Phar......
$2500

Kidney Transplant Rejection Global Clinical Trials Review, H2, 2018

Kidney Transplant Rejection Global Clinical Trials Review, H2, 2018 Summary GlobalData's clinical trial report, "Kidney Transplant Rejection Global Clinical Trials Review, H2, 2018" provides an overview of Kidney Transplant Rejection clinical trials scenario. This report provides top line data relating to the clinical trials on Kidney Transplant Rejection. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary......
$2500

Amyotrophic Lateral Sclerosis: Epidemiology Forecast to 2027

Amyotrophic Lateral Sclerosis: Epidemiology Forecast to 2027 Summary ALS is a rare but fatal progressive neurodegenerative disease that affects the nerve cells in the brain and the spinal cord (Doi et al., 2014). ALS is often referred to as "Lou Gehrig's Disease" after the famous baseball player. ALS severely impacts physical functioning, and initially presents with muscle twitching, weakness in an arm or leg, or sometimes with slurring of speech. Eventually, people with ALS lose their ability to control the muscles needed to move, speak, eat, and breathe, which ultimately leads to death. GlobalData epidemiologists used age- and sex-specific diagnosed prevalence rates to forecast the diagnosed prevalent cases, and used the diagnosis rate and diagnosed prevalence to calculate total......
$3995

Hematology Reagents – Medical Devices Pipeline Assessment, 2018

Hematology Reagents - Medical Devices Pipeline Assessment, 2018 Summary GlobalData's Medical Devices sector report, "Hematology Reagents - Medical Devices Pipeline Assessment, 2018" provides an overview of Hematology Reagents currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Hematology Reagents pipeline products. This report is prepared using data sourced from in-house databases, secondary and primary research by Glo......
$2500

Anemia Tests – Medical Devices Pipeline Assessment, 2018

Anemia Tests - Medical Devices Pipeline Assessment, 2018 Summary GlobalData's Medical Devices sector report, "Anemia Tests - Medical Devices Pipeline Assessment, 2018" provides an overview of Anemia Tests currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Anemia Tests pipeline products. This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry e......
$2500

Hematology Analyzers – Medical Devices Pipeline Assessment, 2018

Hematology Analyzers - Medical Devices Pipeline Assessment, 2018 Summary GlobalData's Medical Devices sector report, "Hematology Analyzers - Medical Devices Pipeline Assessment, 2018" provides an overview of Hematology Analyzers currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Hematology Analyzers pipeline products. This report is prepared using data sourced from in-house databases, secondary and primary research by......
$2500

Thyroid Function Tests – Medical Devices Pipeline Assessment, 2018

Thyroid Function Tests - Medical Devices Pipeline Assessment, 2018 Summary GlobalData's Medical Devices sector report, "Thyroid Function Tests - Medical Devices Pipeline Assessment, 2018" provides an overview of Thyroid Function Tests currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Thyroid Function Tests pipeline products. This report is prepared using data sourced from in-house databases, secondary and primary res......
$4000
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy